突触核蛋白α(SNCa)重组蛋白
Recombinant Synuclein Alpha (SNCa)
SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor
- 编号RPB222Hu01
- 物种Homo sapiens (Human，人)相同的名称，不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位细胞膜, 细胞核, 细胞质
- 预测分子量18.2kDa
- 实际分子量21kDa(差异分析请参阅说明书)
- 片段与标签Met1~Ala140 with N-terminal His Tag
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 95%
- 等电点4.5
- 应用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，请参见活性蛋白。 - 下载英文说明书 中文说明书
- 规格10µg50µg200µg1mg5mg
- 价格¥ 1104¥ 2760¥ 5520¥ 16560¥ 41400
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
产品包装(模拟)
产品包装(模拟)
Figure . Gene Sequencing (extract)
Figure. SDS-PAGE
通过ISO 9001、ISO 13485质量体系认证
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPB222Hu01 | 突触核蛋白α(SNCa)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB222Hu01 | 突触核蛋白α(SNCa)多克隆抗体 | WB; IHC; ICC; IP. |
| LAB222Hu71 | 突触核蛋白α(SNCa)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| MAB222Hu22 | 突触核蛋白α(SNCa)单克隆抗体 | WB; IHC; ICC; IP. |
| SEB222Hu | 突触核蛋白α(SNCa)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEB222Hu | 抗突触核蛋白α抗体(Anti-SNCa)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
参考文献
| 杂志 | 参考文献 |
| The Journal of Clinical Investigation | Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration[PubMed: PMC3428100] |
| Neurobiology of Disease | Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission[PubMed: PMC3107939] |
| Nature Communications | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus[PubMed: PMC3265381] |
| Provisional chapter | Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease[Intechopen:Source] |
| Nerodegeneration | Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment[pubmed:29326545] |
| Experimental gerontology | The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.[pubmed:29107062] |
| Neurobiology of Disease | Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity[Pubmed: 30521842] |
| molecular and cellular biochemistry | Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model[Pubmed: 31820278] |
| International Journal of Pharmacology | Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease[Pubmed: 32084576] |
| EBioMedicine | Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys[Pubmed: 32810825] |